# Insulin Lecture 3

## **Prof. Ahmed Shaaban**


Professor of Pharmacology & Senior Consultant of Endocrinology



# Insulin

Islets of pancreas secrete 5 hormones by 4 cell types:

α (glucagon), β (insulin & amylin), delta (somatostatin) and epsilon (ghrelin). Amylin  $\downarrow$  appetite & food intake, slows gastric emptying and  $\downarrow$  glucagn secretion. Ghrelin  $\uparrow$  appetite & food intake.





- Insulin receptors (in all tissues) consist of 2 extracellular  $\alpha$  subunits (for insulin binding) 2  $\beta$  subunits (along cell membrane with intracellular end carrying tyrosine kinase).
- Insulin binding ↑ phosphorylation of tyrosine kinase causing phosphorylation cascade of proteins with insulin signaling.
- The 1st are the docking proteins insulin receptor substrates
- (IRS-1 .....IRS-6). Then phosphorylation of adaptor proteins.
- This activates enzymes & carrier for transport.
- Insulin receptor number is  $\uparrow$  by  $\downarrow$  body weight, high fiber diet, exercise & oral hypoglycemics.
- Insulin receptor number is  $\downarrow$  by obesity, simple sugars, sedentary life & other hormones.



## Actions

**Anabolic**,  $\rightarrow$  storage of the 3 macronutrients.

- A) On carbohydrates:
- $\uparrow$  uptake, utilization of glucose & storage of glycogen  $\rightarrow$  hypoglycemia.

1.  $\uparrow$  cellular uptake of glucose (with K+) by facilitating its diffusion across cell membranes except in brain, RBC, intestine & kidney. By stimulation of 5 glucose transporters, e.g. Glut 4 in skeletal muscles & fat and Glut 2 in  $\beta$  cells of pancreas for insulin release.

- 2. ↑glycolysis.
- 3.  $\uparrow$ glycogenesis ( $\uparrow$ glycogen storage) in liver & skeletal muscles and  $\downarrow$ glycogenolysis.
- B) On proteins:

 $\uparrow$  cellular uptake of amino acids ( $\uparrow$  amino acids transporters), incorporation integration proteins (anabolic) &  $\downarrow$  gluconeogenesis.

C) On fats:

- 1.  $\downarrow$  lipolysis in fat cells by inhibiting hormone sensitive (intracellular) lipase enzyme  $\rightarrow \downarrow$  FFAs mobilization to blood.
- 2.<sup>↑</sup> lipogenesis:
- Converts glucose  $\rightarrow \rightarrow$  fats mainly in adipose tissue.
- Insulin + lipoprotein lipase are complementary.
- Insulin  $\uparrow$  fat synthesis (from glucose) in liver and  $\uparrow$  blood triglycerides & cholesterol levels. Then lipoprotein lipase (in capillaries)  $\rightarrow$  conversion of triglycerides in lipoprotein to free fatty acids  $\rightarrow$  circulation  $\rightarrow$  export of triglycerides (via VLDL) to adipose tissue. More in metabolic syndrome.
- 3.1 formation &  $\uparrow$  uptake of ketone bodies.

In fed state insulin release †glycolysis, glycogenesis & lipogenesis.

In fasting:  $\uparrow$  growth h., glucagon & epinephrine  $\rightarrow \uparrow$  fatty acids oxidation ( $\rightarrow$  fewer free radicals  $\rightarrow$  antioxidant & antiinflammatory),  $\downarrow$  glucose oxidation &  $\uparrow$  gluconeogenesis  $\rightarrow$  preserve glucose for brain.

D) Vascular insulin actions:  $\uparrow$ NO, VD,  $\downarrow$ vascular smooth m. proliferation,  $\uparrow$ microvascular blood flow &  $\downarrow$ platelet aggregation. <u>Antagonizes renin angiotensin actions which  $\rightarrow$  opposite....&  $\downarrow$ glucose uptake.</u>

- A, B & C : metabolic.
- D : vascular.

## **Control of insulin release**

Normally 50% of daily insulin is basal & 50% PP.


Insulin daily requirements: 0.5- 1 u/Kg. 个in puberty, pregnancy & medical diseases.

#### **Increase by**

1. Glucose  $\rightarrow \uparrow ATP \rightarrow closure of ATP$ - sensitive K+ channels  $\rightarrow depolarization \rightarrow opening of voltage dependent Ca++ channels <math>\rightarrow \uparrow Ca++ influx \rightarrow release of stored insulin (rapid) followed by slow release (newly formed insulin).$ 

The 1st phase (& later phase 2) is impaired in T2DM, both in T1DM.

Amino acids & free fatty acids augment glucose – induced insulin release. Insulinogenic: carbs > proteins > fats.  $K+ \int of$ 



.2. Sulfonylurea: by closing ATP- sensitive K+ channels

3. - 10...

### Decrease by:

1. Hypokalemia by e.g. thiazides, loop diuretics & diazoxide. They are K+ channel openers, increasing K+ efflux  $\rightarrow$  hyperpolarization.....

### **Types of Diabetes Mellitus**

It is a syndrome characterized by disturbance in carbohydrate, protein & fat metabolism beside vascular complications.

Manifested by polyuria, polydepsia, polyphagia,  $\uparrow$  or  $\downarrow$  body wt. &....

Clinical in 16% of population (diagnosed in 8%).

75% of inpatients are diabetics.

B) Secondary diabetes: by endocrine diseases causing hyperglycemia as Cushing disease, acromegaly, pheochromocytoma and by hyperglycemic drugs (type 3). Gestational (pregnancy) diabetes is type 4. In 5-10% of pregnant.  $30 - 60 \% \rightarrow T2DM$ .

#### A) Primary:

#### Type 1 DM (IDDM) Insulin dependent

- Age:
   Young (<30 years)</th>

   At 1-2 & 17 years in 75%.
- **%** < 10%
- **Symptoms**: Appear rapidly, with marked hyperglycemia.
- Ketosis: Common
- **Obesity**: Not common (thin)
  - due to  $\downarrow$ insulin (anabolic)

- Insulin
- ttt.InsulinFamily hist.Not common (10%)

### Type 2DM (NIDDM)

Insulin receptors dependent

Adult (>40 years)

Now.....younger.

> 90%

Slowly, with mild or mod. hyperglycemia.

Rare (insulin is enough to prevent ketosis but not hyperglycemia) Common (the anabolic insulin is present) Variable (↑ then↓) Oral antidiabetics Common



## T1DM

### Type la: >95%. Autoimmune.

Viral infection of  $\beta$ -cells in genetically predisposed pts.

→ mild hyperglycemia → healing & recovery (honey moon period) → autoimmune reactions → destruction of these cells (>90% at diagnosis) → severe hyperglycemia.

Contribution is genetic (1/3) in pts. with HLA-DR3 & 4 (regulate immune response) and environmental (by viruses).

Screening done at time of diagnosis shows high circulating levels of antibodies to insulin and components of insulin receptors .

**Type lb**: <5%. Idiopathic.



### T2DM

A) Hereditary. Contribution is mainly genetic (strong). Mainly in 1st degree family history relatives (parents & siblings).

B) Environmental:

1. Obesity. Mainly visceral (metabolic) obesity more than SC abdominal fat due to its link with insulin resistance.

- 2. 个diet sugars & other drugs with high glycemic or insulin index.
- 3. Lack of exercise.
- 4. Emotions.
- 5. Periodontitis, intestinal dysbiosis and vitamin & mineral deficiency.

**Insulin resistance** (receptor or post-receptor defect)  $\rightarrow$ 

1. 个insulin release.

2.  $\downarrow$  insulin release by exhaustion of  $\beta$ -cells (2ry failure).

#### **Metabolic syndrome**

#### (insulin resistance syndrome, X syndrome)

Most important factor in development of T2DM.

Very common, with many associations:

- 1. 个body wt.
- 2. ↑BP.
- 3. **↑**plasma lipids .
- 4. **A plasma insulin then glucose.**

5.  $\uparrow$  prothrombotic & proinflammatory state ( $\uparrow$ CRP), thrombophilia & oxidative stress. Astherosclerosis.

#### 6. 个uric acid.

7. Fatty liver. NAFLD is better predictor of cardiovascular disease & mortality. Also cholecystitis & gall stones.  $\uparrow$ GGT.

- 8. Polycystic ovary syndrome.
- 9. Rheumatoid arthritis.

# **Causes of metabolic syndrome:**

- 1. Life style....
- 2. Periodontitis:
- Bidirectional relationship between periodontitis & DM.
- Predictor of mortality.
- 3. Intestinal dysbiosis:
- 4. Deficiency of Mg, K, vit. D, omega 3 fatty acids, .... Insulin resistance ttt.:
- 1. Life style modification of diabetics......
- 2. Metformin.
- 3. Pioglitazone (insulin sensitizer).
- 4. ACEIs & ARBs:



### **Stages of diabetes – induced metabolic syndrome**

**A. Impaired glucose tolerance** (prediabetes): 10 years, with complications.

#### **B. Metabolic diabetes**: Hyperglycemia.

Hypoglycemia  $\rightarrow$  many complications as cardiovascular &  $\uparrow$  mortality.

Brittle diabetes is that with unstable blood glucose levels (marked fluctuations). Food  $\rightarrow$  marked hyperglycemia. Normally this is compensated by  $\uparrow$  insulin release  $\rightarrow \uparrow$  glycogen storage &  $\uparrow$  glucose uptake & utilization.  $\downarrow$  insulin activity in diabetics reduces glycogen storage &  $\downarrow$  glucose uptake & utilization. Fasting  $\rightarrow$  hypoglycemia because low glycogen stores cannot supply enough glucose by  $\uparrow$ glycogenolysis induced by other hormones.

**C. Vascular diabetes:** Microvascular (& macrovascular) complications (we are as old as our arteries, carotid intima media thickness).

Tight glycemic control improves micro & not macroangiopathy.

 $\downarrow$ 1% HbA1c  $\rightarrow \downarrow$  microvascular complications by 40% & mortality by15%.

**D. Cancer**: By  $\downarrow$  immunity,  $\uparrow$  insulin $\rightarrow$   $\uparrow$  growth..., cancer cells need glucose